Företrädesemissionen i Panion Animal Health AB tecknades till cirka 1,3 miljoner kronor, motsvarande cirka 17,4 procent av emissionen. Med företrädesrätt tecknades 1 294 491 aktier, motsvarande cirka 16,8 procent. Panion tillförs därmed cirka 1,3 miljoner kronor före emissionskostnader om cirka 150 000 kronor. Genom teckning och tilldelning nyemitteras 1 337 365 aktier. Avräkningsnotor är planerade att skickas ut den 2 januari 2019. Aktier och aktiekapital efter företrädesemissionen uppgår till 1 137 110,723 kronor fördelat på 24 399 487 aktier. Handel med betalda tecknade aktier (BTA) pågår fram till dess att företrädesemissionen har registrerats av Bolagsverket vilket beräknas ske i januari 2019.

Utöver ovan avslutade emissionen har följande avtal slutits:
* kliniken Long Island Veterinary Specialists, Ophthalmology, Surgery, Internal Medicine, Emergency, PLLC (“LIVS”) in New York, USA, skall genomföra försöken och reducerar kostnaden med 50 000 USD. “LIVS” erhåller detta belopp i aktier i en separat riktad emission.
* Styrelsemedlemmen Dede Willis samt affärsutvecklingsansvarige Carlos Veles tecknar aktier i en separat riktad emission. Beloppet i denna emission uppgår till 10 000 USD.

Under den aktuella perioden har processen om ytterligare en kapitalinjektion om 450 000 USD inletts, denna process beräknas vara slutförd under Q1(-19).

Panion Animal Heath AB
Styrelsen

The rights issue was subscribed for at 17.4 percent

The rights issue in Panion Animal Health AB was subscribed for approximately SEK 1.3 million, corresponding to approximately 17.4 percent of the issue. Existing shareholders with preferential rights subscribed for 1,294,491 shares, corresponding to approximately 16.8 percent. Panion is thus allocated approximately SEK 1.3 million before issue costs of approximately SEK 150,000. By subscription and allotment 1,337,365 shares are issued. Settlement notes are scheduled to be sent out on January 2, 2019. Shares and share capital after the rights issue amount to SEK 1,137,110,723 divided into 24,399,487 shares. Trading in paid subscribed shares (BTA) is ongoing until the rights issue has been registered by the Swedish Companies Registration Office, which is expected to take place in January 2019.

In addition to the issue completed above, the following agreements have been concluded;
* Long Island Veterinary Specialists Clinics, Ophthalmology, Surgery, Internal Medicine, Emergency, PLLC in New York, USA (LIVS) shall carry out the study and reduces the cost by USD 50,000. “LIVS” receives this amount in shares in a separate directed issue.
* Board member Dede Willis and director of business development Carlos N. Veles subscribe for shares in a separate directed issue. The amount in this issue amounts to USD 10,000.

During the current period, the process of additional capital injection of USD 450,000 has been initiated, this process is expected to be completed during Q1 2019.

Panion Animal Heath AB
Board of Directors